Latest News

New Phase 3b Interim Data from STARDUST Study Show Two-Thirds of Patients with Moderately to Severely Active Crohn’s Disease Achieved Clinical Remission After Two Doses of STELARA® (ustekinumab)





VIENNA–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson today announced interim data from the Phase 3b STARDUST study. At week 16, 79 percent of patients with moderately to severely active Crohn’s disease (CD) achieved clinical responsea and 67 percent were in clinical remissionb after receiving one ~6 mg/kg intravenous (IV) dose followed by one 90 mg subcutaneous (SC) dose of STELARA® (ustekinumab), open label.1 Intestinal ultrasound (IUS) responses were assessed

Source link




Related posts

Princeton researchers find link between microbes and cancers in threatened California foxes

Newsemia

Medical News Today: How to relieve laryngitis symptoms at home

Newsemia

Elasticity vs. Hyperelasticity Considerations in Quasi-Static Modelling of a Soft Finger-like Robotic Appendage for Realtime Position & Force Estimation

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy